Q1 revenue rose 13% with payments growth. FY2027 EBITDA margin target near 25% depends on operating leverage. AccessOne financing adds execution risk.
Alpha Score of 64 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
Phreesia (PHR) set its FY2027 revenue guidance at $510 million to $520 million while holding adjusted EBITDA in a $125 million to $135 million range. The outlook came alongside the company’s Q1 FY2027 earnings call, where management reported 13% year-over-year revenue growth and highlighted payments segment expansion. An update on AccessOne financing added a layer of execution risk that investors will need to weigh against the top-line trajectory.
The $510M-$520M revenue range implies a deceleration from the 13% Q1 growth rate if the full-year midpoint is compared against the prior year’s base. Adjusted EBITDA of $125M-$135M is unchanged from the previous target, suggesting management expects margin improvement to offset any revenue mix shifts. The EBITDA margin implied by the midpoint is roughly 25%, a level that requires continued operating leverage in the software and payments platform.
Q1 revenue rose 13% year over year, driven by client additions and higher payment volumes. The payments segment – which processes patient copays and balances – grew faster than the subscription software line, a dynamic that typically improves take rate but adds processing cost variability. Gross margin in the payments business is lower than software, so the mix shift will pressure consolidated gross margin unless scale benefits materialize.
AccessOne, Phreesia’s patient financing arm, received a financing update during the call. The unit provides installment payment plans to patients, and its capital requirements depend on default rates and lender appetite. Any tightening in credit availability or rise in delinquencies could force Phreesia to allocate more cash to support the portfolio, reducing free cash flow available for share repurchases or debt reduction. The FY2027 EBITDA guidance does not appear to assume a material change in AccessOne’s funding structure, yet the risk is worth monitoring in subsequent quarters.
Client retention and new logo additions will determine whether the $510M-$520M revenue target is achievable. Healthcare providers are under margin pressure, which could slow upgrade cycles for Phreesia’s patient intake software. On the other hand, regulatory mandates for price transparency and digital check-in create a tailwind for adoption. The next catalyst is the Q2 FY2027 report, where payments volume growth and AccessOne portfolio performance will be the key metrics to watch.
For a broader view of how healthcare technology companies are navigating the current rate environment, see our stock market analysis. Investors comparing brokerages for trading these names can review the best stock brokers.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.